Zydus Lifesciences Q4 Results 2025: 23% YoY Net Profit Reported, Shares Drop 1.25% Post-Earnings Announcement

Pharmaceutical major Zydus Lifesciences has announced its financial results for the fourth quarter and full year ended March 31, 2025, showcasing robust operational performance despite a slight dip in net profit. The company reported a consolidated net profit of Rs 1,171 crore for Q4 FY25, compared to Rs 1,183 crore in the same period last year. It also delivered strong growth in revenue and EBITDA, highlighting its resilience and strategic execution across key markets.

Zydus Lifesciences Managing Director (MD) Dr Sharvil Patel said while declaring earnings, "We are happy to conclude FY 2025 on a strong note, with all our businesses surpassing our growth expectations. The commercial success of our extensive product portfolio combined with operating leverage has significantly bolstered profitability and financial health. We made meaningful progress in our differentiated pipeline and added new capabilities to ensure sustainable growth."

Zydus Lifesciences Q4 Results 2025

Zydus Lifesciences reported a consolidated net profit of Rs 1,171 crore for the fourth quarter, reflecting a marginal decline of 1% compared to Rs 1,183 crore in the same period last year. Despite the dip in bottom-line performance, the company delivered a robust operational performance, with revenue rising 18% year-on-year to Rs 6,528 crore, up from Rs 5,533 crore.

Zydus Lifesciences EBITDA: Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) of the company rose 30.3% year-on-year to Rs 2,126 crore, compared to Rs 1,630.5 crore, driven by higher efficiencies and better product mix. Revenue grew 18% to Rs 6,528 crore, up from Rs 5,533 crore, while EBITDA margin improved to 32.6% from 29.5%, reflecting stronger underlying business performance.

Zydus Lifesciences FY 2025 Business Performance

For the full year FY25, Zydus Lifesciences saw strong growth. The company's revenue from operations reached Rs 2,32,41.5 crore, a rise of 19% compared to last year. They also spent Rs 18,55.5 crore on research and development, which is 8% of their total revenue. Their EBITDA increased by 31%, reaching Rs 70,58.5 crore, and their EBITDA margin improved by 2.9 percentage points to 30.4%. The company's net profit, after adjusting for exceptional items, grew by 23%, reaching Rs 47,45.1 crore.

"We look forward to continued execution success and deepening strategic partnerships to drive long-term growth. Our commitment to maintaining the highest quality standards across our operations remains unwavering," said the company MD.

Zydus Lifesciences Q4 2025 Final Dividend Recommended: Check Recording Date

The pharma company's Board has recommended a final dividend of Rs 11 per equity share of face value Rs 1 each, representing a 1100% payout. This dividend is subject to shareholder approval. The approval will be sought at the Annual General Meeting (AGM) scheduled for August 12, 2025.

This is a notable rise from last year's final dividend of Rs 6 per share and nearly three times the Rs 3 dividend declared in FY24. Over the past ten years, Zydus has generally paid dividends in the range of Rs 2.50 to Rs 6, making this year's payout exceptional.

Zydus Lifesciences Ltd Share Price After Q4 2025 Earnings Call

Following the earnings announcement, shares of Zydus Lifesciences Ltd. were trading 1.25% lower at Rs 899.85 as of May 20, 2025, 1:38 PM. On a year-to-date basis, the stock has declined by 8%.